Pegfilgrastim vs filgrastim

EMA has approved a biosimilar to filgrastim Zarzio, on the basis of its comparable quality, safety and efficacy to filgrastim. Given that pegfilgrastim is more convenient to administer as a single treatment per chemotherapy cycle, there is considerable interest in comparing pegfilgrastim with filgrastim for clinical efficacy and cost

Prophylaxis with pegfilgrastim was significantly associated with lower FN-related chemotherapy disruption rates (8.3 vs 17.3% in the pegfilgrastim and filgrastim groups, respectively) and fewer FN-related days in hospital (0 vs 15 days, respectively).

Use of pegfilgrastim vs short-acting G-CSF. Clinical trial data suggest a similar efficacy and safety profile with pegfilgrastim and 11 days filgrastim. 1 If 11 days filgrastim is not utilized, pegfilgrastim should be given in preference to a reduced duration of daily filgrastim (consensus reached (91%); evidence level I).

Results: Medical records of 624 pts from 34 sites receiving pegfilgrastim or filgrastim have been abstracted to date. Pegfilgrastim was initiated in 351(56%) pts and filgrastim was initiated in 273 (44%) pts. Of the 624 pts, 120 (19%) received both pegfilgrastim and filgrastim (no pt used both products in the same cycle).

FDA Approved Drugs Listings in Neutropenia Neulasta (pegfilgrastim) Neupogen (filgrastim) Neutroval (tbo-filgrastim) Rolvedon (eflapegrastim-xnst)

Take medications filgrastim (Neupogen) tbo-filgrastim (Granix) pegfilgrastim (Neulasta) eflapegrastim (Rolvedon).

During Consolidation, nonprophylactic anti-infective use was higher in the pegfilgrastim (82%) versus the filgrastim (67%) group. However, the median (interquartile range) duration of use was similar in the two groups (pegfilgrastim 21 (20, 33) vs filgrastim 21.5 (18, 35.5) days). The incidence and duration of hospitalization was similar in the

Pegfilgrastim (Filed with EMA) Filgrastim (Filed with EMA) Trastuzumab vs. COX-1. The Orodispersible tablets enhance patient compliance

Hospital length of stay was longer in the tbo-filgrastim arm with a median of 20.73 days vs 19.61 days in the pegfilgrastim arm (P = .0032). Patients in the tbo-filgrastim group compared to the pegfilgrastim group had an increased incidence of neutropenic fever (76.7% vs 50.9%, P = .0034). Cost was assessed as well assessing average whole sale